17.0% of FHLC Holdings Experiencing Recent Insider Purchases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2025
0mins
Source: NASDAQ.COM
Insider Buying Activity: 17.0% of the weighted holdings in the Fidelity MSCI Health Care Index ETF (FHLC) have seen insider buying in the past six months.
Avantor Inc (AVTR): This company, making up 0.12% of FHLC, has had two directors and officers purchase shares recently, with the ETF holding $3,215,377 worth of AVTR.
Establishment Labs Holdings Inc (ESTA): Representing approximately 0.02% of FHLC, ESTA has also seen insider purchases from two directors and officers, with the ETF holding $490,723 worth of ESTA.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESTA
Wall Street analysts forecast ESTA stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 71.230
Low
75.00
Averages
82.88
High
90.00
Current: 71.230
Low
75.00
Averages
82.88
High
90.00
About ESTA
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. successfully debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and a fully diluted total of 35,238,222 shares, marking a significant advancement in regenerative medicine and enhancing its market competitiveness.
- Innovative Product Launch: The company unveiled its 3D bioprinted regenerative breast matrix, B.R.E.A.S.T.™, designed to provide a temporary scaffold for patients post-mastectomy, targeting over 100,000 women annually who opt out of reconstruction, thus opening a larger market opportunity.
- Platform Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and targeting multi-billion-dollar markets in wound care, periodontal applications, and facial contouring, indicating vast market potential.
- Regulatory Strategy: The company plans to submit a 510(k) application in early 2027, transitioning its products from investigational to commercial status, further solidifying its leadership position in the regenerative medicine sector.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and 35,238,222 on a fully diluted basis, marking a significant advancement in regenerative medicine and expected to enhance its market competitiveness.
- Innovative Product Launch: The company unveiled B.R.E.A.S.T.™, a 3D-printed regenerative breast matrix designed to provide a temporary scaffold for women post-mastectomy, addressing a market gap faced by over 100,000 women annually, indicating substantial market potential.
- Platform Technology Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and is expected to drive expansion into multi-billion-dollar markets such as wound care, periodontal applications, and facial contouring, enhancing overall business growth potential.
- Regulatory Outlook: The company plans to submit a 510(k) application in early 2027, marking a transition from preclinical to commercialization; if approved, this will open new revenue streams and bolster investor confidence.
See More
Founder Juan José Chacón Quirós Sells 105,000 Shares Indirectly
- Indirect Share Sale: Founder and former CEO Juan José Chacón Quirós indirectly sold 105,000 shares through Sariel Group Ltd for approximately $7.92 million, representing 9.74% of his total holdings, indicating his continued confidence in the company's future.
- Ownership Structure Analysis: Post-transaction, Chacón Quirós retains 45,193 direct shares and 927,504 indirect shares, with direct ownership valued at around $3.37 million, underscoring his significant position within the company remains intact.
- Historical Trading Comparison: This sale marks the largest single transaction by Chacón Quirós to date, reflecting a constraint on future direct share transactions, which may impact his trading strategy going forward.
- Future Trading Outlook: With all shares under the December 2025 10b5-1 plan now sold, any future trading will require a new plan or rely on open-market trading windows, potentially increasing uncertainty in the sales cadence.
See More
Founder Sells 105,000 Shares Indirectly
- Share Sale Overview: Founder and former CEO Juan José Chacón Quirós indirectly sold 105,000 shares of Establishment Labs Holdings Inc. on May 6, 2026, generating approximately $7.92 million at a weighted average price of $75.42 per share, reducing indirect holdings to 927,504 shares while direct holdings remain at 45,193 shares.
- Financial Performance Highlights: On the same day, the Q1 earnings report revealed U.S. revenue of $19.6 million, reflecting a 13.3% increase from Q4 2025, and the company achieved its third consecutive quarter of positive adjusted EBITDA, indicating strong financial performance and growth potential.
- Strategic Plan Impact: The share sale was pre-scheduled under a 10b5-1 plan adopted in December 2025, and although it coincided with the earnings release, it does not reflect performance expectations, suggesting the founder maintains an optimistic outlook on the company's future development.
- Future Outlook: The company raised its full-year guidance and is targeting positive free cash flow in the second half of 2026, with a reconstruction approval application pending, which could provide new momentum for future growth.
See More
Establishment Labs Reports 45% Revenue Growth in Q1 2026
- Strong Revenue Growth: Establishment Labs Holdings Inc reported $59.9 million in revenue for Q1 2026, reflecting a 45% year-over-year increase, indicating robust market performance and growth potential.
- Exceptional U.S. Performance: The U.S. business experienced a remarkable 216% revenue growth, primarily driven by the successful launch of the Motiva platform, showcasing rapid market penetration and increased customer acceptance.
- Improved Gross Margin: Gross margin improved by 350 basis points to 70.7%, reflecting enhanced operational efficiency and increased sales of higher-margin products, which further strengthens the company's profitability.
- Raised Full-Year Guidance: The company raised its full-year revenue guidance to $266.5 million to $268.5 million, demonstrating confidence in continued growth despite geopolitical uncertainties and ongoing financial pressures.
See More
Establishment Labs Reports Strong Q1 2026 Earnings with Increased Guidance
- Significant Revenue Growth: Establishment Labs reported $59.9 million in revenue for Q1 2026, reflecting nearly 45% growth year-over-year, demonstrating strong performance in the U.S. market, particularly achieving quarter-over-quarter growth in a seasonally light quarter, which validates the acceleration of its market launch.
- Positive Adjusted EBITDA: The company achieved an adjusted EBITDA of $1.2 million in Q1, a substantial turnaround from a loss of $12.1 million in the same quarter last year, marking the third consecutive quarter of positive EBITDA, indicating ongoing improvements in profitability and operational efficiency.
- Increased Full-Year Guidance: Establishment Labs raised its full-year revenue guidance to $266.5 million to $268.5 million, up from the previous range of $264 million to $266 million, reflecting strong confidence in market demand, particularly as U.S. order counts hit new weekly highs.
- Positive Cash Flow Outlook: Management expects to achieve cash flow positive status in the second half of 2026 and has successfully refinanced its credit facility, showcasing robust financial management and confidence in future growth prospects.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. successfully debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and a fully diluted total of 35,238,222 shares, marking a significant advancement in regenerative medicine and enhancing its market competitiveness.
- Innovative Product Launch: The company unveiled its 3D bioprinted regenerative breast matrix, B.R.E.A.S.T.™, designed to provide a temporary scaffold for patients post-mastectomy, targeting over 100,000 women annually who opt out of reconstruction, thus opening a larger market opportunity.
- Platform Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and targeting multi-billion-dollar markets in wound care, periodontal applications, and facial contouring, indicating vast market potential.
- Regulatory Strategy: The company plans to submit a 510(k) application in early 2027, transitioning its products from investigational to commercial status, further solidifying its leadership position in the regenerative medicine sector.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and 35,238,222 on a fully diluted basis, marking a significant advancement in regenerative medicine and expected to enhance its market competitiveness.
- Innovative Product Launch: The company unveiled B.R.E.A.S.T.™, a 3D-printed regenerative breast matrix designed to provide a temporary scaffold for women post-mastectomy, addressing a market gap faced by over 100,000 women annually, indicating substantial market potential.
- Platform Technology Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and is expected to drive expansion into multi-billion-dollar markets such as wound care, periodontal applications, and facial contouring, enhancing overall business growth potential.
- Regulatory Outlook: The company plans to submit a 510(k) application in early 2027, marking a transition from preclinical to commercialization; if approved, this will open new revenue streams and bolster investor confidence.
See More
Founder Juan José Chacón Quirós Sells 105,000 Shares Indirectly
- Indirect Share Sale: Founder and former CEO Juan José Chacón Quirós indirectly sold 105,000 shares through Sariel Group Ltd for approximately $7.92 million, representing 9.74% of his total holdings, indicating his continued confidence in the company's future.
- Ownership Structure Analysis: Post-transaction, Chacón Quirós retains 45,193 direct shares and 927,504 indirect shares, with direct ownership valued at around $3.37 million, underscoring his significant position within the company remains intact.
- Historical Trading Comparison: This sale marks the largest single transaction by Chacón Quirós to date, reflecting a constraint on future direct share transactions, which may impact his trading strategy going forward.
- Future Trading Outlook: With all shares under the December 2025 10b5-1 plan now sold, any future trading will require a new plan or rely on open-market trading windows, potentially increasing uncertainty in the sales cadence.
See More
Founder Sells 105,000 Shares Indirectly
- Share Sale Overview: Founder and former CEO Juan José Chacón Quirós indirectly sold 105,000 shares of Establishment Labs Holdings Inc. on May 6, 2026, generating approximately $7.92 million at a weighted average price of $75.42 per share, reducing indirect holdings to 927,504 shares while direct holdings remain at 45,193 shares.
- Financial Performance Highlights: On the same day, the Q1 earnings report revealed U.S. revenue of $19.6 million, reflecting a 13.3% increase from Q4 2025, and the company achieved its third consecutive quarter of positive adjusted EBITDA, indicating strong financial performance and growth potential.
- Strategic Plan Impact: The share sale was pre-scheduled under a 10b5-1 plan adopted in December 2025, and although it coincided with the earnings release, it does not reflect performance expectations, suggesting the founder maintains an optimistic outlook on the company's future development.
- Future Outlook: The company raised its full-year guidance and is targeting positive free cash flow in the second half of 2026, with a reconstruction approval application pending, which could provide new momentum for future growth.
See More
Establishment Labs Reports 45% Revenue Growth in Q1 2026
- Strong Revenue Growth: Establishment Labs Holdings Inc reported $59.9 million in revenue for Q1 2026, reflecting a 45% year-over-year increase, indicating robust market performance and growth potential.
- Exceptional U.S. Performance: The U.S. business experienced a remarkable 216% revenue growth, primarily driven by the successful launch of the Motiva platform, showcasing rapid market penetration and increased customer acceptance.
- Improved Gross Margin: Gross margin improved by 350 basis points to 70.7%, reflecting enhanced operational efficiency and increased sales of higher-margin products, which further strengthens the company's profitability.
- Raised Full-Year Guidance: The company raised its full-year revenue guidance to $266.5 million to $268.5 million, demonstrating confidence in continued growth despite geopolitical uncertainties and ongoing financial pressures.
See More
Establishment Labs Reports Strong Q1 2026 Earnings with Increased Guidance
- Significant Revenue Growth: Establishment Labs reported $59.9 million in revenue for Q1 2026, reflecting nearly 45% growth year-over-year, demonstrating strong performance in the U.S. market, particularly achieving quarter-over-quarter growth in a seasonally light quarter, which validates the acceleration of its market launch.
- Positive Adjusted EBITDA: The company achieved an adjusted EBITDA of $1.2 million in Q1, a substantial turnaround from a loss of $12.1 million in the same quarter last year, marking the third consecutive quarter of positive EBITDA, indicating ongoing improvements in profitability and operational efficiency.
- Increased Full-Year Guidance: Establishment Labs raised its full-year revenue guidance to $266.5 million to $268.5 million, up from the previous range of $264 million to $266 million, reflecting strong confidence in market demand, particularly as U.S. order counts hit new weekly highs.
- Positive Cash Flow Outlook: Management expects to achieve cash flow positive status in the second half of 2026 and has successfully refinanced its credit facility, showcasing robust financial management and confidence in future growth prospects.
See More
